Earnings roundup
A slew of tri-county public companies have reported earnings over the past trading week. Here is a breakdown of the companies’ latest financial statements.
ATARA BIO
Thousand Oaks-based Atara Biotherapeutics, a pre-revenue biotechnology company, reported financial results for the second quarter of 2026 and business updates on Aug. 12.
Atara reported a net loss of $4.8 million, or a basic and diluted loss per share of 32 cents, for the second quarter 2026, as compared to net income of $2.4 million, or basic earnings per share of 20 cents and diluted earnings per share of 19 cents, for the same period in 2025.
Cash, cash equivalents and short-term investments as of June 30 totaled $9.9 million, as compared to $8.4 million as of March 31.
Atara expects that its cash, cash equivalents and short-term investments, combined with operating efficiencies achieved in 2025 and the first half of 2026, will be sufficient to fund planned operations into mid-2027.
On May 7, Atara announced that it had a “productive meeting” with the FDA to find a potential path forward to resubmitting the tab-cel Biologics License Application.
In the May 7 meeting, the FDA agreed that a single-arm study using an appropriate historical control applicable to the trial population, conducted in a pre-specified manner, could serve as an adequate and well-controlled study and provide safety and efficacy data in support of a future marketing application of tab-cel for the proposed indication.
Atara stock closed at $9.60 on Aug. 19, a 12% rise over the last five trading days.
ARCUTIS
Westlake Village-based Arcutis Biotherapeutics, which specializes in developing therapies in immunodermatology, reported financial results for the quarter ended June 30 on Aug. 5.
The company reported that revenues for the quarter ended June 30 were $129.9 million compared to $81.5 million for the corresponding period in 2025.
The company’s main product, Zoryve, continues to be the main driver of Arcutis’ growth. Zoryve is a highly potent and selective phosphodiesterase-4 (PDE4) inhibitor treatment in many different formulations that are approved in the United States and Canada for the treatment of plaque psoriasis, atopic dermatitis and seborrheic dermatitis.
Zoryve net product sales for the second quarter of 2026 were $129.9 million, reflecting 59% year-over-year growth and a 23% sequential increase versus the first quarter of 2026.
Moreover, net income was $15 million, or 11 cents per basic and diluted share, for the quarter compared to a net loss of $15.9 million, or 13 cents per basic and diluted share, for the corresponding period in 2025, as continued sales growth exceeded increases in operating expenses.
Cash and cash equivalents were $238.9 million as of June 30. Net cash provided by operating activities was $12.6 million during the second quarter.
Arcutis stock closed at $26.46 on Aug. 19.
INOGEN
Goleta-based Inogen, a maker of portable oxygen concentrators, reported financial results for the second quarter on Aug. 6.
Total revenue in the second quarter of 2026 was $95.1 million, an increase of 3% from $92.3 million in the prior-year period, primarily driven by higher demand for portable oxygen concentrators, or POCs, in international markets and the favorable impact of foreign exchange rates.
GAAP net loss for the second quarter of 2026 was $3.9 million compared to a net loss of $4.2 million in the prior-year period. Adjusted net loss improved $0.6 million year-over-year to less than $0.1 million in the second quarter of 2026, compared with an adjusted net loss of $0.7 million in the prior-year period.
Cash, cash equivalents, marketable securities and restricted cash were $106.8 million as of June 30 with no debt outstanding. The company repurchased 1,145,150 shares of its common stock in the first half of 2026 for consideration of $7.5 million under the share repurchase program that was announced in the first quarter of 2026.
Inogen stock closed at $5.68 on Aug. 19.
email: [email protected]
